Emerging Biomarkers in the Assessment of Alzheimer’s Disease

Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

These activities are designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This webcast and podcast will help participants understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.

Faculty:

Amitava Dasgupta, Ph.D.
Kelsey Woodard, MLS (ASCP)

These activities are designed to introduce pathologists, laboratory managers/directors, and laboratory professionals to emerging research in biomarker testing (cerebral spinal fluid [CSF] and blood-based biomarkers) and imaging for the detection of Alzheimer’s disease. 

You will learn about the biological significance and the clinical implications of these biomarkers, as well as how to utilize the AT(N) framework for Alzheimer’s disease diagnosis and biomarker classification. Additionally, you will also learn about the limitations of current biomarkers for Alzheimer’s disease and directions for future research.